

Current Effective Date: 12/19/24

Status: Approved

Reviewed by Medical Policy Subcommittee: 06/24/16, 2/7/19, 8/3/23, 12/19/24

Reviewed Dates: 06/24/16, 1/8/19, 1/6/22, 2/3/22, 6/16/23, 12/2/24

INSTRUCTIONS FOR USE DISCLAIMER:

SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

Gender Reassignment Surgery Policy

Indication/Usage:

Gender dysphoria refers to discomfort or distress that is caused by a discrepancy between an individual's gender identity and the gender assigned at birth. A diagnosis of gender dysphoria requires a marked difference between the individual's expressed/experienced gender and the gender others would assign him or her, and it must continue for at least six months. This condition may cause clinically significant distress or impairment in social, occupational or other important areas of functioning. Gender affirming surgery is performed to change primary and/or secondary sex characteristics.

.

Medical Indications for Authorization Commercial and Medicare Members

Indication/Usage: Gender reassignment surgery is considered medically necessary when all of the following criteria are met:

1. Hormone Therapy Puberty Blockers

Gonadotropin-releasing hormone (GnRH) analog treatment for gender non-conforming adolescents seeking to delay puberty is covered. GnRH analogs may be used to either allow members more time for decision making purposes or as an initial step prior to further gender affirming services such as hormone therapy. Treatment options include but are not limited to:

- Goserelin (Zoladex)
- Histrelin (Supprelin LA)
- Leuprolide (Lupron Depot-Ped, Fensolvi)
- Triptorelin (Trelstar, Triptodur)

The following criteria are recommended by World Professional Association for Transgender Health (WPATH) Standards as the minimum criteria prior to starting puberty suppressing hormones:

1. The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed)
2. Gender dysphoria emerged or worsened with the onset of puberty
3. Any co-existing psychological, medical, or social problems that could interfere with treatment have been addressed, such that the adolescent's situation and functioning are stable enough to start treatment
4. The adolescent has given informed consent and, particularly when the adolescent has not reached the age of medical consent, the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process.

Gender Affirming Hormone

Therapy Gender affirming hormone therapy is covered at the discretion of the treating provider. Gender affirming hormone therapy options include but are not limited to

- Estrogen
- Androgen Reducing Medications (bicalutamide, spironolactone, GnRH agonists, 5-alpha reductase inhibitors)
- Progestin and Testosterone

Refer to plan document for coverage of all hormone therapy for gender dysphoria

Gender affirming surgery in members under the age of 18

All of the following criteria must be met for members under the age of 18 before any gender reaffirming surgery.

Consideration may be given for a gender affirming treatment in select adolescent individuals between the start of puberty through 17 years of age. Extenuating circumstances should be carefully considered, such as the level of maturity of the individual, duration and severity of dysphoric symptoms, coexisting medical and mental health issues. A provider with experience treating adolescents with gender dysphoria is required.

Gender diversity/incongruence is marked and sustained over time:

- Meets the diagnostic criteria of gender incongruence in situations where a diagnosis is necessary to access health care;
- Demonstrates the emotional and cognitive maturity required to provide informed consent/assent for the treatment;
- Mental health concerns that may interfere with diagnostic clarity, capacity to consent, and gender-affirming medical treatments have been addressed; sufficiently so that gender affirming medical treatment can be provided optimally.
- Informed of the reproductive effects, including the potential loss of fertility and the available options to preserve fertility;
- At least 12 months of gender-affirming hormone therapy or longer, if required, to achieve the desired surgical result for gender-affirming procedures, including breast augmentation, orchiectomy, vaginoplasty, hysterectomy, phalloplasty, metoidioplasty, and facial surgery as part of gender-affirming treatment unless hormone therapy is either not desired or is medically contraindicated.

2. Requirements for mastectomy for female-to-male patients:

- a. Single letter of referral from a qualified mental health professional; **and**
- b. Persistent, well-documented gender dysphoria; **and**
- c. Capacity to make a fully informed decision and to consent for treatment; **and**
- d. If significant medical or mental health concerns are present, they must be reasonably well controlled
- e. Members less than 18 years of age must complete 1 year of testosterone treatment unless it is medically contraindicated or not desired

Note: A trial of hormone therapy is not a pre-requisite to qualifying for a mastectomy

3. Requirements for Breast Augmentation (Implants/Lipofilling)

- a. Single letter of referral from a qualified mental health professional (see Appendix); *and*
- b. Persistent, well-documented gender dysphoria (see Appendix); *and*
- c. Capacity to make a fully informed decision and to consent for treatment; *and*

- d. Completion of one year of feminizing hormone therapy prior to breast augmentation surgery for adults and adolescents under the age of 18 unless the member has a medical contraindication or is otherwise medically unable to take hormones; *and*
- e. If significant medical or mental health concerns are present, they must be reasonably well controlled.

Note: More than one breast augmentation is considered not medically necessary.

4. **Requirements for Gonadectomy** (hysterectomy and oophorectomy in female-to-male and Orchiectomy in male-to-female):

- a. Two referral letters from qualified mental health professionals, one in a purely evaluative role; **and**
- b. Persistent, well-documented gender dysphoria; **and**
- c. Capacity to make a fully informed decision and to consent for treatment; **and**
- d. If significant medical or mental health concerns are present, they must be reasonably well controlled; **and**
- e. Twelve months of continuous hormone therapy as appropriate to the member's gender goals for adults and adolescents under the age of 18 unless the member has a medical contraindication or is otherwise unable or unwilling to take hormones.

5. **Requirements for genital reconstructive surgery** (i.e., vaginectomy, urethroplasty, metoidioplasty, phalloplasty, scrotoplasty, and placement of a testicular prosthesis and erectile prosthesis in female to male; penectomy, vaginoplasty, labiaplasty, and clitoroplasty in male to female):

- a. Two referral letters from qualified mental health professionals, one in a purely evaluative role; **and**
- b. Persistent, well-documented gender dysphoria; **and**
- c. Capacity to make a fully informed decision and to consent for treatment; **and**
- d. If significant medical or mental health concerns are present, they must be reasonably well controlled; **and**
- e. Twelve months of continuous hormone therapy as appropriate to the member's gender goals for adults and adolescents under the age of 18 unless the member has a medical contraindication or is otherwise unable or unwilling to take hormones; **and**
- e. Other possible causes of apparent gender incongruence have been excluded

6. **SummaCare considers reversal of gender affirming surgery for gender dysphoria not medically necessary.**

Note on gender specific services for the transgender community:

Gender-specific services may be medically necessary for transgender persons appropriate to their anatomy. Examples include:

- Breast cancer screening may be medically necessary for female to male trans identified persons who have not undergone a mastectomy;
- Prostate cancer screening may be medically necessary for male to female trans identified persons who have retained their prostate;
- SummaCare considers gonadotropin-releasing hormone medically necessary to suppress puberty in trans identified adolescents if they meet World Professional Association for Transgender Health (WPATH) criteria.

Limitations

SummaCare consider the following procedures that may be performed as a component of a gender reassignment as cosmetic (not an all-inclusive list):

- Abdominoplasty
- Blepharoplasty
- Body contouring
- Brow lift
- Calf implants
- Cheek/malar implants
- Chin/nose implants
- Collagen injections
- Construction of a clitoral hood
- Drugs for hair loss or growth
- Face lift
- Facial bone reduction
- Facial feminization and masculinization surgery
- Feminization of torso
- Forehead lift
- Facial bone reduction
- Facial feminization and masculinization surgery
- Feminization of torso
- Hand feminization and masculinization
- Jaw reduction (jaw contouring)
- Hair removal
- Hair transplantation
- Lip reduction/ enhancement
- Liposuction
- Mastopexy
- Neck tightening
- Pectoral implants
- Removal of redundant skin
- Rhinoplasty

- Skin resurfacing (dermabrasion/chemical peel)
- Tracheal shave (reduction thyroid chondroplasty)
- Voice modification surgery
- Voice therapy/voice lessons

Note: Rhinoplasty, face-lifting, lip enhancement, facial bone reduction, blepharoplasty, breast augmentation, liposuction of the waist (body contouring), reduction thyroid chondroplasty, hair removal, voice modification surgery (laryngoplasty or shortening of the vocal cords), and skin resurfacing, which have been used in feminization, are considered cosmetic. Similarly, chin implants, nose implants, and lip reduction, which have been used to assist masculinization, are considered cosmetic.

CMS NCD ID 140.9 NCD Title Gender Dysphoria and Gender Reassignment Surgery

The Centers for Medicare & Medicaid Coverage (CMS) conducted a National Coverage Analysis that focused on the topic of gender reassignment surgery. Effective August 30, 2016, after examining the medical evidence, CMS determined that no national coverage determination (NCD) is appropriate at this time for gender reassignment surgery for Medicare beneficiaries with gender dysphoria. In the absence of an NCD, coverage determinations for gender reassignment surgery, under section 1862(a)(1)(A) of the Social Security Act (the Act) And any other relevant statutory requirements, will continue to be made by the local Medicare Administrative Contractors (MACs) on a case-by-case basis.

Limitations

SummaCare considers all of the cosmetic for all other indications.

Coverage Decisions

Coverage decisions made per CMS Guidelines, Hayes Research and industry standards research

Plans Covered By This Policy

Commercial and Medicare

Self-funded Commercial groups refer to plan document for coverage

Sources Reviewed

The World Professional Association for Transgender Health (WPATH), “Standards of Care for the Health of Transgender and Gender Diverse People, 8th version, 2022.

de Vries, A.L., McGuire, J.K., Steensma, T.D., et al. “Young Adult Psychological Outcome After Puberty Suppression and Gender Reassignment”, *PEDIATRICS*, 134(4), 2014, pp. 696-704. 7.

Kuper, L. E., Stewart, S., Preston, S., Lau, M., & Lopez, X. (2020). Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy. *Pediatrics*, 145(4). <https://doi.org/10.1542/peds.2019-3006>.

Green, A. E., DeChants, J. P., Price, M. N., & Davis, C. K. (2021). Association of GenderAffirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth. *Journal of Adolescent Health*, 70(4). <https://doi.org/https://doi.org/10.1016/j.jadohealth.2021.10.036>

Rimes, K., Goodship N., Ussher, G., Baker, D. and West, E. (2019). Non-binary and binary transgender youth: Comparison of mental health, selfharm, suicidality, substance use and victimization experiences. *International Journal of Transgenderism*, 20 (2-3); 230-240.

Price-Feeney, M., Green, A. E., & Dorison, S. (2020). Understanding the mental health of transgender and nonbinary youth. *Journal of Adolescent Health*, 66(6), 684–690. <https://doi.org/10.1016/j.jadohealth.2019.11.314> 4 Trevor Project. (2021). National Survey on LGBTQ Youth Mental Health 2021. Trevor Project. <https://www.thetrevorproject.org/survey2021/>.

Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. *Int J Transgend*. 2022; 23 sup1:S1-S259.

Oles N, Darrach H, Landford W, et al. Gender affirming surgery: A comprehensive, systematic review of all peer-reviewed literature and methods of assessing patient-centered outcomes (Part 1: Breast/chest, face, and voice). *Ann Surg*. 2022;275(1):e52-e66

Oles N, Darrach H, Landford W, et al. Gender affirming surgery: A comprehensive, systematic review of all peer-reviewed literature and methods of assessing patient-centered outcomes (Part 2: Genital reconstruction). *Ann Surg*. 2022;275(1):e67-e74.

Lee J, Nolan IT, Swanson M, et al. A review of hand feminization and masculinization techniques in gender affirming therapy. *Aesthetic Plast Surg*. 2021;45(2):589-601.

Rafferty J; Committee on Psychosocial Aspects of Child and Family Health; Committee on Adolescence; Section on Lesbian, Gay, Bisexual, and Transgender Health and Wellness. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. *Pediatrics*. 2018;142(4).

Hayes, Inc. Hayes Directory Report. Sex reassignment surgery for the treatment of gender dysphoria. Lansdale, PA: Hayes, Inc.; August 2018; updated July 2021.

Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/GenderIncongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol

Metab. 2017 Nov 1;102(11):3869-3903.

<https://academic.oup.com/jcem/article/102/11/3869/4157558>

Mahfouda S, Moore JK, Siafarikas A, Hewitt T, Ganti U, Lin A, Zepf FD. Gender-affirming hormones and surgery in transgender children and adolescents. Lancet Diabetes Endocrinol.

2019 Jun;7(6):484-498

Gender Dysphoria and Gender Reassignment Surgery CMS

<https://www.cms.gov/medicarecoveredatabase/view/ncd.aspx?NCID=368>